ALPEGA
16.7.2024 10:01:29 CEST | Business Wire | Press release
Alpega is excited to announce the return of Connecta, the premier networking event in the European road transport sector, celebrating its 14th edition. Scheduled for October 10th and 11th, 2024, at the prestigious Marriott Auditorium Conference Center in Madrid, this year's event promises to be the most comprehensive and impactful yet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716487251/en/
(Photo: Business Wire)
Unparalleled Networking Opportunities
With over 500 professionals from across Europe expected to attend, Connecta 2024 will offer unmatched networking opportunities. Participants can generate significant business prospects within a single day, thanks to a meticulously planned agenda of networking activities. This event brings together the major players in the market, offering attendees a unique platform to engage in meaningful conversations and forge valuable connections.
A Full Logistics Network Representation
For the first time, Connecta 2024 will feature all logistics network participants, including carriers, freight forwarders, and shippers. This comprehensive representation ensures a holistic view of the industry, facilitating deeper insights and collaboration across different segments of the transport sector.
Showcasing the Latest Innovations
Connecta 2024 will also be a platform to showcase the latest innovations in the logistics sector. Attendees will have the opportunity to explore cutting-edge solutions and technologies that are transforming the industry, providing valuable insights into future trends and advancements.
Expanded Agenda with Key Panels and Workshops
The 2024 edition of Connecta boasts an expanded agenda, beginning on Thursday afternoon with a series of key panels and workshops. We are excited to confirm an inaugural session with Boston Consulting Group (BCG), led by Jesus Montero, Lead Knowledge Analyst in Logistics, presenting insightful analysis on industry trends alongside major sector players. Additionally, attendees can look forward to a networking workshop led by the renowned Jose Maria Salles, providing practical tools and strategies for effective networking.
Why Attend Connecta 2024?
“Connecta is more than just a networking event; it's a pivotal moment for the European logistics community to come together, share insights, and drive innovation. This year's edition will be our most impactful yet, offering unparalleled opportunities to connect, learn, and grow,” said Todd DeLaughter, CEO of Alpega.
- Engage with Industry Leaders: Meet and converse with top influencers and decision-makers in the European road transport industry.
- Generate Business Opportunities: Utilize tailored networking activities to create valuable business prospects in a single day.
- Gain Industry Insights: Attend sessions and panels led by industry experts, including a detailed analysis of current trends by BCG.
- Comprehensive Network Representation: Benefit from the presence of carriers, logistics operators, and shippers, offering a complete view of the transport chain.
- Discover Innovations: Explore the latest technologies and solutions shaping the future of logistics.
Don’t miss this unparalleled opportunity to connect, learn, and grow within the European road transport sector. Join us at Connecta 2024 and be part of the conversation shaping the future of the industry.
Registration and Additional Information
For more details and to register for Connecta 2024, please visit our official website Alpega Connecta. Special early bird prices are available until July 31st.
About Alpega
Alpega is a global leader in logistics SaaS software, dedicated to delivering comprehensive end-to-end solutions for all transport requirements. Our mission is to empower shippers, forwarders, and carriers through efficient digitalization, addressing today’s logistics challenges and driving smarter logistics for a greener tomorrow.
Leveraging extensive carrier-based assets, Alpega provides tangible benefits in Transport Execution, Freight Planning, Freight Sourcing and Payment, Dock Scheduling, and Data Insights. As the only SaaS provider offering Transport Management Systems (TMS) for shippers, and with an 80,000-strong open carrier network that covers about 10% of all commercial trucks in Europe, we lead in innovation and efficiency.
Our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we help businesses streamline their supply chain planning and execution, reducing costs and increasing visibility. Our community of 80,000 carriers and 200,000 members is seamlessly connected daily, efficiently managing vital transport operations. This network harnesses the power of collective intelligence, driving data-driven insights and optimizations across the logistics ecosystem, and creating a network effect that adds significant value for our customers. Operating in 80 countries, Alpega boasts a diverse team of over 450+ professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716487251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom